SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis

Digestive Diseases and Sciences

Volumn 44, Issue 2, 1999, Pages 439-444

  Di Sebastiano, P ^a,b   Grossi, L ^a,b   Di Mola, F F ^a,b   Angelucci, D ^a,b   Friess, H ^a,b   Marzio, L ^a,b   Innocenti, P ^a,b   Buchler M W ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Experimental colitis; Histology; Smooth muscle contractility; Substance P receptor antagonist

Indexed keywords

NOLPITANTIUM; SUBSTANCE P ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLITIS; DRUG EFFECT; EDEMA; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTION;

EID: 0032933192     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026639509036     Document Type: Article

References (26)

1. 1. Chaudary NA, Traveler SC: Human colonic motility: a comparative study of normal subjects, patients with ulcerative colitis and patients with irritable bowel syndrome. I. Resting patterns of motility. Gastroenterology 40:1-17, 1961
2. 2. Grossi L, McHugh K, Collins SM: On the specificity of altered muscle function in experimental colitis in rats. Gastroenterology 104:1049-1056, 1993
3. 3. Vermillion D, Collins SM: Increased responsiveness of jejunal longitudinal muscle in Trichinella-infected rats. Am J Physiol 254:G124-G129, 1988
4. 4. Weihe E, Krekel J: The neuroimmune connection in human tonsils. Brain Behav Immun 5:41-54, 1991
5. 5. Hagermark O, Hokfelt T, Pernow B: Flare and itch induced by substance P in human skin. J Invest Dermatol 71:233-235, 1978
6. 6. Lembeck F, Holzer P: Substance P as neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation. Naunyn-Schmiedeberg's Arch Pharmacol 310:175-183, 1979
7. 7. Lembeck F: Substance P and sensory neurons. In Substance P. Metabolism and Biological Actions. CC Jordan, P Oehme (eds). London, Taylor and Francis, 1985, pp 137-151
8. 8. Levine JD, Moskowitz MA, Basbaum AI: The contribution of neurogenic inflammation in experimental arthritis. J Immunol 135:843s-846s, 1985
9. 2, capsaicin and substance P. Acta Physiol Scand 112:331-338, 1981
10. 10. Büchler M, Weihe E, Friess H, Malfertheiner P, Bockman DE, Müller S, Nohr D, Beger HG: Changes in peptidergic innervation in chronic pancreatitis. Pancreas 7:183-192, 1992
11. 11. Fink T, Di Sebastiano P, Büchler MW, Beger HG, Weihe E: Growth-associated protein-43 and protein gene-product 9.5 innervation in human pancreas: Changes in chronic pancreatitis. Neuroscience 63(1):249-266, 1994
12. 12. Di Sebastiano P, Fink T, Weihe E, Friess H, Beger HG, Büchler M: Changes of protein gene product 9.5 in the inflamed appendix. Dig Dis Sci 40(2):366-372, 1995
13. 13. Di Sebastiano P, Fink T, Weihe E, Friess H, Innocenti P, Beger HG, Büchler MW: Immune cells infiltration and growth associated protein-43 correlate with pain in chronic pancreatitis. Gastroenterology 112:1648-1655, 1997
14. 14. Bjorck S, Dahlstrom A, Johansson L, Ahlman H: Treatment of the mucosa with local anesthetics in ulcerative colitis. Agents Actions 35(suppl):C60-C72, 1992
15. 15. Pernov B: Substance P: Present status and future prospects. In Substance P. Metabolism and Biological Actions. CC Jordan, P Oehme (eds). London, Taylor and Francis, 1985, pp 187-196
16. 16. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803, 1989
17. 17. Emonds-Alt X, Doutremepuich JD, Heaulme M, Neliat G, Santucci V, Steinberg R, Vilain P, Bichon D, Ducoux JP, Proietto V, Van Brock D, Soubrié P, Le Fur G, Brelière JC: In vitro and in vivo biological activities of SR 140333, a novel potent non-peptide tachykinin NKI receptor antagonist. Eur J Pharmacol 250:403-413, 1993
18. 18. Barrett KE: Neurogenic inflammation in the intestine. Gastroenterology 108:295-296, 1995
19. 19. McCafferty DM, Sharkey KA, Wallace JL: Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol 266:G560-G567, 1994
20. 20. Pothoulakis C, Castagliuolo I, LaMont TJ, Jaffer A, O'Keane JC, Snider RM, Leeman SE: CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin but not cholera toxin. Proc Natl Acad Sci USA 91:947-951, 1994
21. 21. Wallace JL, MacNaughton WK, Morris GP, Beck PL: Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96:29-36, 1989
22. 22. Higa A, McKnight GW, Wallace JL: Attenuation of epithelial injury in acute experimental colitis by immunomodulators. Eur J Pharmacol 239:171-176, 1993
23. 23. Elson CO, Balfour Sartor R, Tennyson GS, Riddel RH: Experimental models of inflammatory bowel disease. Gastroenterology 109:1344-1367, 1995
24. 24. Fax-Robichaud AE, Collins SM: Altered calcium-handling properties of jejunal smooth muscle from nematode-infected rats. Gastroenterology 91:1462-1469, 1986
25. 25. Cohen JD, Kao HW, Tau ST, Lechago J, Snape WS: Effects of acute experimental colitis on rabbit colonic smooth muscle. Am J Physiol 251:G538-G545, 1986
26. 26. Renzi D, Calabro A, Panerai C, Tramontana M, Evangelista S, Milani S, Surrenti C: Decreased substance P and neurokinin A tissue levels are associated with enhanced beta-preprotachikinin gene expression in experimental TNB-colitis. Gastroenterology 108:A902, 1995